Infant spinal anesthesia with levobupivacaine has been promoted as a technique to reduce both the risk of postoperative apnea and exposure to volatile anesthesia. There is, however, no pharmacokinetic data to support the currently recommended doses.Aims:
Our aim was to determine whether infant levobupivacaine spinal anesthesia is associated with plasma concentrations consistent with a low risk of local anesthetic systemic toxicity.Methods:
This was an open-label pharmacokinetic safety and tolerability study of levobupivacaine spinal anesthesia in infants <55 weeks Post Menstrual Age undergoing lower abdominal surgery. Infants received a spinal anesthetic with levobupivacaine 1 mg·kg−1 in the left lateral position.Results:
Spinal anesthesia was successful in 25 (86.2%) of 29 infants (postmenstrual age 36–52 weeks; weight 2.2–4.7 kg). The median (IQR) total venous levobupivacaine plasma concentrations was 0.33 (0.25–0.42) μg·ml−1 and unbound venous levobupivacaine was 19.5 (14.5–38) ng·ml−1. Median protein binding was 93.5 (91.4–96%). Alpha-1 acid glycoprotein concentrations were 0.25 (0.17–0.37) g·l−1 and albumin concentrations were 29 (24–32) g·l−1.Conclusion:
Total plasma concentrations and unbound (free) concentration of levobupivacaine were consistently lower than concentrations reported in cases of pediatric local anesthetic toxicity. In a small number of infants requiring a repeat spinal of 1 mg·kg−1 was also associated with acceptable total and free concentrations. We conclude that levobupivacaine at 1 mg·kg−1 is associated with no systemic side effects in infants receiving awake spinal anesthesia.